DUBLIN--(BUSINESS WIRE)--The "Cancer Biomarkers Market by Type, Cancer Type, Profiling Technology, Application - Global Forecast to 2022" report has been added to Research and Markets' offering.
The Global Cancer Biomarkers Market Is Projected to Reach USD 20.48 Billion by 2022 from USD 11.53 Billion in 2017
Over the years, the cancer biomarkers market has evolved significantly owing to the rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies. However, an unfavorable regulatory and reimbursement scenario and the high capital investments required for biomarker development and validation are some factors expected to restrain the market.
The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin's lymphoma, kidney, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing company focus on research on lung cancer biomarkers is the key driver for this market. Increased understanding of the morphology of lung carcinogenesis, development of the high-throughput techniques for biomarker discovery, and increased focus on early detection of cancer are propelling the growth of this market.
North America (comprising the US and Canada) is expected to account for the largest share of the global cancer biomarkers market in 2017. The large share of this geographic segment is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region.
While the APAC region is expected to register the highest CAGR during the forecast period. The APAC cancer biomarkers market, particularly in China, Japan, and India is expected to witness high growth during the forecast period.
Major players in this market that are profiled in the report includes Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), Hologic (US), Danaher (US), and Shimadzu (Japan).
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Cancer Biomarkers Market, By Biomarker Type
7 Cancer Biomarker Market, By Cancer Type
8 Cancer Biomarkers Market, By Profiling Technology
9 Cancer Biomarkers Market, By Application
10 Cancer Biomarkers Market, By Region
11 Competitive Landscape
12 Company Profiles
- Abbott Laboratories
- Agilent Technologies
- Becton, Dickinson and Company
- Bio-Rad Laboratories
- Biomrieux SA
- Danaher Corporation
- GE Healthcare
- Merck & Co.
- Myriad Genetics
- Qiagen N.V.
- Quest Diagnostics
- Roche Diagnostics
- Sysmex Corporation
- Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/research/sb97nh/cancer_biomarkers